Oral acyclovir was evaluated for its effectiveness in treating guinea pigs with primary herpes simplex virus type 2 infections. Guinea pigs inoculated intravaginally with acyclovir-susceptible strains (for which 50% inhibitory concentrations of acyclovir in cell culture were found to be in the range of 0.15 to 1.2 ,ug/ml) and treated with 5.0 mg of acyclovir per ml in the drinking water beginning 48 h postinfection showed significant reductions in lesion severity. This dosage produced serum acyclovir levels of 1.3 ,ug/ml. Lower concentrations of oral acyclovir (c2.5 mg/ml in the drinking water), which produced serum acyclovir levels of less than 1.0 ,ug/ml, were less consistently effective against these same virus strains. When an acyclovir-resistant isolate (for which the 50% inhibitory concentration of acyclovir in cell culture was found to be 8.5 ,ug/ml) was used to initiate infection, treatment with 5 or 10 mg/ml (yielding serum levels of 1.3 and 3.5 ,ug/ml) in the drinking water had only minimal clinical benefit. However, the degree of response was difficult to determine because of the attenuated disease produced by the acyclovir-resistant virus. In vitro virus sensitivity may be predictive of the serum drug levels that need to be obtained to produce a successful response to therapy.
Herpes simplex virus (HSV) can become significantly less susceptible to acyclovir inhibition upon exposure to acyclovir in vitro (5) and in vivo (2) (3) (4) . Although such viruses have been termed "resistant," what such categorization means with respect to response to therapy is uncertain. Some patients treated with acyclovir have shed virus with decreased in vitro susceptibility to acyclovir, yet their lesions have healed quite rapidly (2), whereas others have shed susceptible virus from persisting lesions for a protracted period (20) .
Studies set forth in this report represent an attempt to determine relations between in vitro susceptibility, plasma drug levels, and therapeutic response. Guinea pigs were infected with several HSV type 2 (HSV-2) isolates and treated with different concentrations of orally administered acyclovir, and their response to therapy was compared with the serum levels of drug achieved.
( 12 female Hartley strain guinea pigs (Dutchland) weighing 200 to 250 g each were inoculated intravaginally with 0.2 ml of the appropriate virus strain. Guinea pigs were caged in groups of two in a room with a controlled light and dark cycle. The inoculum containing approximately 105 to 106 PFU produced infections in 85 to 90% of recipients.
Cell cultures and virus stocks. Primary guinea pig embryo (GPE) cells were prepared from 30-to 40-day pregnant Hartley strain guinea pigs as previously described (1) . Pools of HSV-2 isolates were grown in Vero (African green monkey kidney) cells (Flow Laboratories, Inc., Rockville, Md.). Three of the four viruses used in these studies were clinical isolates obtained from patients enrolled in acyclovir * Corresponding author.
clinical trials. They are VL6092, VL6093, and VL7897; VL6093 is thymidine kinase deficient. The fourth strain, MSII, was obtained from Earl Kern, University of Utah School of Medicine, Salt Lake City.
Administration of acyclovir. The sodium salt of acyclovir was reconstituted at specified concentrations in sterile distilled water and administered to guinea pigs in their drinking water. Fresh drug solutions were provided in the drinking water every 24 h for the 10 or 14 days of the experiment.
Grading of primary lesions. Lesions appearing on the external genital skin were scored daily through 10 days according to previously described criteria (16) .
Isolation of virus from vaginas of infected guinea pigs. The vagina of each guinea pig was swabbed at 1, 3, 5, 7, and 10 days postinfection. Samples were titrated in Vero cells by a dye-uptake (DU) method (14) . Antiviral susceptibility assays. Virus isolates used in the studies were tested for their susceptibility to drug inhibition in both Vero and GPE cells by a standard plaque reduction (PR) assay. Briefly, confluent monolayers of Vero or GPE cells were inoculated with 0.2 ml of a suspension containing approximately 150 PFU of virus. A 1-h period for adsorption of virus at 37°C was allowed in an atmosphere of 5% CO2 in 95% air, and plates were then overlaid with twofold dilutions of drug contained in 5-ml overlay of Eagle minimum essential medium supplemented with 2% newborn calf serum (M.A. Bioproducts, Walkersville, Md.), 0.5% immune serum globulin (Cutter Laboratories, Berkeley, Calif.), 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer (GIBCO Laboratories, Grand Island, N.Y.), sodium bicarbonate, 75 U of penicillin 9, and 75 p.g of streptomycin per ml. After incubation for 3 days at 37°C, the overlays were removed, and the cell monolayers were stained with 1% crystal violet dissolved in a mixture of Formalin, acetic acid, methanol, and water (2:1:16:6). Each assay included eight drug dilutions and cell and virus control plates. Plaque counts from duplicate plates were used to determine the drug concentration inhibiting 50% of the control plaques (ED50) for each virus strain. Results were obtained using a computer probability analysis (version 79.3 of procedure PROBIT; Statistical Analysis Systems, Raleigh, N.C.) (7) . Viral isolates were also tested for drug sensitivity in Vero cells by a DU method as described previously (14) . Acyclovir ED50s obtained in the DU assay are generally 10-fold higher than those determined by the standard PR method.
Plasma drug levels. At 1 and 5 days after initiation of drug therapy, two animals in each group were bled by cardiac puncture for the determination of plasma acyclovir levels.
Plasma concentrations of acyclovir were determined by a sensitive radioimmunoassay technique (17) .
Statistical analysis. The area under the mean-lesion-score curve, calculated by using the trapezoidal rule, was chosen as a summary measure of the severity of the infection. A linear regression line was fitted by the method of least squares with the area under the curve as the response and the dose of acyclovir as the independent variable. After the estimates of the slope and intercept were obtained, they were used to derive the estimate of an in vivo ED50, the dose of acyclovir that caused a 50% reduction in the area under the curve from the untreated control. This in vivo ED50 was then translated into a corresponding plasma level. Mean lesion scores were measured for statistical significance by the Kruskal-Wallis test. RESULTS Acyclovir susceptibilities. The ED50 values of the HSV-2 isolates used in these studies are shown in. Table 2 . Guinea pigs that drank water containing 5.0 mg of acyclovir per ml had plasma levels of 1.22 to 1.49 ,ug/ml, whereas animals drinking water containing 10 mg/ml had plasma levels of 2.5 to 6.5 p.g/ml. The were not significantly different from controls. However, In previous studies (11), acyclovir treatment, whether syseven control animals had more attenuated disease when temic (intraperitoneal) or combined systemic (oral) and infected with this resistant virus. As in previous experitopical, begun after the onset of clinical disease had minimal ments, vaginal virus titers were not reduced by treatment at effect on genital HSV-1 infection. However, there was either concentration.
benefit from such treatment in infections caused by HSV-2 In vitro in vivo ratios. From these data, we have derived an (11) . Prior studies of topical acyclovir may have been in vivo ED50 by linear regression analysis, which calculated hampered by the limited permeability of guinea pig skin. In the dose of acyclovir that produced a 50% reduction in the studies with orally administered acyclovir (10), the concenarea under the curve of the mean lesion score. As depicted in tration of drug administered was low because of the limited Table 1 , there is a general correlation between the in vitro solubility of acyclovir base (1.3 mg/ml in water at 22°C). In ED50 for a virus and the amount of drug necessary to reduce the present studies, this limitation was overcome by using mean lesion scores by 50%, although viruses tested in GPE the sodium salt of acyclovir, which is considerably more cells were somewhat less susceptible (acyclovir ED50 5 times soluble (>100 mglml in water at 22°C) and consumed readily higher) to the antiviral effect of acyclovir than were those by guinea pigs. tested in Vero cells. The ratio of acyclovir ED50s as deterAlthough the guinea pig model has been quite useful in the mined in GPE by the PR method and the in vivo ED50s evaluation of new antiviral agents, it must be noted that in approximated 1. The one exception to this is observed with some regards this model is considerably different from its VL7897, which was extremely virulent.
human counterpart. For examnple, plasma acyclovir levels delivered in drinking water are higher and more sustained in DISCUSSION guinea pigs than are generally achieved with oral therapy in Acyclovir has been shown to be effective in a variety of humans (19) . Conversely, guinea pig tissues may be less forms in reducing the severity of genital herpetic disease in sensitive to acyclovir, as shown in our in vitro susceptibility guinea pigs (10, 11, 13, 15, 16) . The degree of clinical studies, because of increased intracellular levels of thymiresponse may be modified depending upon the amount of dine (6) . Nevertheless, this model provides a useful framedrug administered, the formulation used, and the length of work for establishing the relationship between in vitro time between viral infection and the initiation of therapy (9) . susceptibility and clinical response to therapy. In the present study, oral acyclovir at a dose of 5.0 mg/ml in the drinking water produced serum levels of approximately 1.3 p.g/ml and was highly effective against HSV-2 strains with in vitro acyclovir ED50s between 0.15 and 1.2 ,ug/ml. With acyclovir doses of 1.25 mg/ml or less (yielding serum levels of 0.44 to 0.65 ptg/ml), the drug was less consistently effective against these same virus strains. The degree of clinical response appeared to be influenced not only by the susceptibility of the virus to acyclovir, but also by the virulence of the isolate. Variable effects of acyclovir therapy with different virus strains have been reported previously (12, 13) . Furthermore, oral acyclovir doses of 5 or 10 mg/ml (yielding serum levels of 1.3 or 4.5 ,ug/ml, respectively) produced only moderate clinical responses against a resistant HSV-2 virus (acyclovir ED50 of 8.5 ,ug/ml), although the evaluation of the degree of response was difficult because of the attenuated nature of this infection.
The issue of correlation between in vitro susceptibility of causative organism with clinical outcome and level of antimicrobial drug in the serum is a complicated one. Although there have been intuitive expectations that there is a direct correlation between in vitro and in vivo susceptibility of viruses to acyclovir, no data to date, however, have been presented to support this hypothesis, and there are several reasons to suspect that the precise in vitro susceptibility of a virus may not be synonymous with the precise in vivo susceptibility. In vitro susceptibilities for an individual isolate may vary up to 100-fold depending upon the cell substrate or technique employed (14) . It should also be remembered that in vitro assays are usually performed by continuous exposure of the virus to a constant level of drug and are expressed as the level that inhibits only 50% of the virus present. In patients, however, the virus is exposed to various levels of drug, clinical response is dependent upon the elimination of virtually all replicating virus, and numerous factors such as varied tissue distribution, host immunity, viral virulence, and individual variations of drug absorption, distribution, and excretion are all operative (21) .
The data from the present study suggest that in guinea pigs there is only a general correlation between in vitro acyclovir susceptibility, plasma acyclovir levels, and the effectiveness of drug therapy in vivo. In the experiments in which drug therapy was highly effective in reducing the extent of genital disease, serum acyclovir levels were achieved that closely approximated the in vitro susceptibility of the virus, with in vivo/in vitro ratio of approximately 1. Nevertheless, such a general correlation was altered by one isolate (VL7897), which was extremely susceptible to acyclovir, but was highly pathogenic. Genital disease produced by acyclovirresistant virus was only moderately and inconsistently reduced by drug treatment. However, in this instance, serum drug levels never reached levels equivalent to those necessary to inhibit the virus in vitro. Disease produced by viruses with decreased in vitro susceptibility to acyclovir might be treated effectively if higher acyclovir levels are attained in the infected host as, for example, by intravenous administration (18) .
These correlations are at best a rough approximation to be used as a therapeutic guideline. Clinical responsiveness has been correlated with HSV-1 isolates with acyclovir ED50s of 0.11 ,ug/ml (PR method), whereas persistent disease has been associated with viral isolates with acyclovir ED5os by the PR assay of >1 ,ug/ml (18) . Examples of poor in vitro/in vivo correlations have been reported (8) . Although these studies have begun to elucidate some of the factors that affect in vivo/in vitro ratios, they are limited by the number of viruses studied as well as by the single species used as a model. Additional studies are necessary with more isolates in several species before more definitive statements can be made concerning the optimum dosage of acyclovir required to treat a virus of known in vitro susceptibility. The use of acyclovir-resistant mutants that retain animal virulence would be important to evaluate in this system. Therapeutic ranges of serum acyclovir concentrations in humans will only be defined by careful in vitro susceptibility studies of virus from sufficient numbers of patients shedding isolates of reduced suceptibility.
